ClinicalTrials.gg
CompletedNCT05995912Updated Oct 10, 2024

Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain

A Phase 2 interventional study of etoricoxib-tramadol and Naproxen in Acute Pain and Postoperative Pain, sponsored by Laboratorios Liomont. Completed at 1 site in Mexico. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Laboratorios Liomont · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Sep 2021, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Acute Pain with a site in Mexico — none open to participants now, none under way, none of them phase 3. Acute Pain · Mexico.

Enrollment
9th of 12
58 · median 150
Started
2021
with 1 other
Phase 2
Only one
of the 12
Registered
8th of 12
by date
Lead sponsor
1 of 12
Laboratorios Liomont

Among the 12 studies in Acute Pain with a site in Mexico, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 2, and was the 8th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

None of the 12 studies in Acute Pain with a site in Mexico is open now. The open studies under Acute Pain, anywhere →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Acute Pain with a site in Mexico as a file.
02

Study summary

The goal of the present phase IIb clinical trial was to compare the safety and efficacy of the fixed-dose combination etoricoxib-tramadol 120mg/100mg tablet (once a day, for three days) versus naproxen 220mg tablet plus tramadol 50 mg capsule in patients with acute postoperative pain after impacted third molar extraction. The main research question was: Is the analgesic efficacy of etoricoxib-tramadol 120mg/100mg tablet non-inferior to naproxen 220 mg tablet + tramadol 50 mg capsule in a clinical model of moderate to severe acute pain? After informed consent, patients were randomly assigned to one of the two arms: test product (etoricoxib-tramadol 120mg/100mg tablet) or active comparator (naproxen 220mg tablet + tramadol 50 mg capsule). After surgery, patients were requested to start the treatment with study drugs (test product was administered once daily for three days; meanwhile reference drug was administered twice a day for three days).

Investigators compared the effects of both treatments on pain intensity at different time frames using the visual analogue scale. Furthermore, the safety of investigational drugs was assessed during the study.

03

Conditions studied

  • Acute Pain
  • Postoperative Pain

Keywords

  • Etoricoxib-tramadol
  • Third molar extraction
  • Analgesia
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes aged from 18 to 40 years.
  • Patients who agreed to participate in the study by signing the .
  • Patients with indication for surgical extraction of impacted lower third molars according to the Pell and Gregory classification.
  • Healthy subjects or with history of controlled chronic non-communicable diseases or that can be controlled prior to surgery, which, in the investigator's opinion, do not represent an additional risk for the patient.
  • Patients who, at the investigator's discretion, meet personal and family conditions that allow them to properly comply with the activities described in the protocol and adherence to treatment.

Exclusion criteria

Exclusion Criteria:

  • Findings in the clinical history, vital signs, physical examination or laboratory studies suggesting abnormal conditions which represent a risk for subject's health at the investigator´s discretion.
  • to any of the active ingredients and/or of the drugs.
  • Patients with active peptic or gastroduodenal ulcer or diagnosis 30 days prior to signing the .
  • Patients with history of allergic asthma reactions.
  • Patients with severe hepatic dysfunction, classified as C or when being less, the investigator considers it an additional risk for patients.
  • Patients with a \<30 mL/min.
  • Patients with coagulation disorders.
  • Patients with Systemic Lupus Erythematosus.
  • Patients with congestive heart failure ( class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease who have recently (3 months) undergone coronary artery bypass grafting or angioplasty procedures.
  • Patients at high risk of acute cardiovascular events (intense smoking, hypertension or uncontrolled diabetes mellitus).
  • Patients with a history of systemic neoplastic diseases or under treatment with chemotherapy.
  • Patients with a history of illicit drug abuse or addiction to alcohol or tobacco.
  • Patients with monoamine oxidase inhibitors (MAOIs) treatment or during the last 2 weeks prior to the study drug administration.
  • Patients with opioid analgesics, neuromodulators, or long-acting NSAIDs therapy who, according to medical criteria, cannot carry out a withdrawal scheme for at least five half-lives prior to surgery.
  • Patients with history of seizures or who are under treatment with medications that reduce the seizure threshold and who, according to medical criteria, cannot carry out a withdrawal scheme within 30 days prior to surgery.
  • Positive pregnancy test or lactating women.
  • Positive rapid urine drug test.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Etoricoxib-Tramadol

    Etoricoxib-Tramadol 120mg/100mg tablet, once-daily, for 3 days

    Drug: etoricoxib-tramadol

  • Active comparator
    Naproxen + Tramadol

    Naproxen 220 mg tablet + Tramadol 50 mg capsule, twice a day, for 3 days.

    Drug: Naproxen · Drug: Tramadol

Interventions

  • Drugetoricoxib-tramadol

    Oral administration (with or without food)

  • Oral administration (with or without food)

  • Oral administration (with or without food)

06

What researchers measure

Primary outcomes

  1. Pain intensity difference (PID)

    The difference in pain intensity at 4 h after drug administration versus time 0 (baseline, before dosing)

    Time frame: At 4 h (Day 0, postdosing) respect the baseline (Day 0, before dosing)

Secondary outcomes

  1. Pain intensity difference (PID)

    The difference in pain intensity at 1, 2, 3, 6, 12, 24, 48, and 72 hours after drug administration versus time 0 (baseline, before dosing)

    Time frame: At 1, 2, 3, 6, 12, 24, 48, and 72 hours postdosing respecto the baseline (Day 0, before dosing)

  2. Total pain relief (TOTPAR)

    TOTPAR is a time-weighted measure of AUC or total area under the pain relief curve and is a summary measure that integrates serial assessments of a subject's pain over the duration of the study or in any time frime.

    Time frame: At 4, 6, 12, 24, 48, 72 hours postdosing respect to the baseline (Day 0, before dosing)

  3. Trismus control

    Measurement the difference of mouth opening (in mm) at baseline (before dosing) and at the end of the study (Day 7).

    Time frame: At the end of the study (Day 7) respect to the baseline (Day 0, before dosing)

  4. Adverse events

    Characteristics and frequency of adverse events

    Time frame: From informed consent (Day -28) to the end of the study (Day 7)

07

Study locations

1 site
  • Oaxaca Site Management Organization
    Oaxaca, 68000, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2022, 10 months.

Of 41 phase 2 interventional studies under Acute Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 16, 2023
StartActual
Sep 29, 2021
Primary completionActual
Aug 18, 2022
CompletionActual
Oct 14, 2022
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05995912
Lead sponsor
Laboratorios Liomont
Collaborators
Infinite Clinical Research, S.A. de C.V.
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Sep 29, 2021
Primary completion
Aug 18, 2022
Completion
Oct 14, 2022
Last update
Oct 10, 2024

Study contacts

Tania A. Sibaja Ponce, M.D.
principal investigator · Oaxaca Site Management Organization, S.C.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion